FDA panel unanimously backs Gilead's hepatitis C drug sofosbuvir

WASHINGTON (Reuters) - A federal advisory panel recommended on Friday that U.S. health regulators approve Gilead Sciences Inc's experimental hepatitis C drug sofosbuvir.

via Reuters: Health News Read More Here..